Most-engaged members lost 25.2% more weight at week 40 and persisted 2.2x longer on medication program than least-engaged members using the Noom app, demonstrating the benefits of combining GLP-1 medication with Nooms GLP-1 Companion behavior-change program PRINCETON, N.J., February 4, 2026 Noom, the leading behavior change company, today shared new real-world findings from tens of thousands of members, showing a clear relationship: members who engage more with Nooms leading GLP-1 Companion app tend to lose more weight and stay on a medication program longer
People who regained more weight also saw increases in waist circumference, blood pressure, non-HDL cholesterol, hemoglobin A1c, and fasting insulinmarkers that had improved while they were on tirzepatide
Because both medications work in similar ways, you may experience similar side effects, such as stomach problems and changes in blood sugar levels
OHearn, M
This gives you flexibility but also adds another variable that must be calculated correctly